Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report) shares reached a new 52-week high on Monday . The company traded as high as $314.00 and last traded at $310.6340, with a volume of 23480 shares traded. The stock had previously closed at $305.71.
Wall Street Analysts Forecast Growth
A number of equities research analysts have commented on KRYS shares. Weiss Ratings upgraded Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, April 9th. Chardan Capital increased their price target on Krystal Biotech from $220.00 to $323.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. HC Wainwright reaffirmed a “buy” rating and issued a $310.00 target price on shares of Krystal Biotech in a research report on Monday, May 4th. The Goldman Sachs Group raised their price objective on Krystal Biotech from $206.00 to $327.00 and gave the company a “buy” rating in a research report on Friday, January 30th. Finally, Evercore reissued an “outperform” rating and issued a $300.00 price objective on shares of Krystal Biotech in a research report on Tuesday, May 5th. Ten analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $324.11.
Check Out Our Latest Stock Analysis on Krystal Biotech
Krystal Biotech Stock Up 2.1%
Krystal Biotech (NASDAQ:KRYS – Get Free Report) last posted its quarterly earnings results on Monday, May 4th. The company reported $1.83 EPS for the quarter, topping analysts’ consensus estimates of $1.45 by $0.38. The business had revenue of $116.36 million during the quarter, compared to the consensus estimate of $112.11 million. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%. Analysts predict that Krystal Biotech, Inc. will post 7.98 earnings per share for the current year.
Insider Buying and Selling
In other news, Director Dino A. Rossi sold 18,950 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $261.41, for a total transaction of $4,953,719.50. Following the completion of the transaction, the director directly owned 78,691 shares in the company, valued at approximately $20,570,614.31. The trade was a 19.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $263.21, for a total value of $6,580,250.00. Following the transaction, the insider owned 1,403,155 shares of the company’s stock, valued at approximately $369,324,427.55. This represents a 1.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 116,664 shares of company stock valued at $31,136,828. 13.10% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Krystal Biotech
Several hedge funds and other institutional investors have recently made changes to their positions in the business. EFG Asset Management North America Corp. raised its holdings in Krystal Biotech by 18.4% during the third quarter. EFG Asset Management North America Corp. now owns 27,095 shares of the company’s stock worth $4,784,000 after purchasing an additional 4,217 shares in the last quarter. Public Sector Pension Investment Board increased its holdings in shares of Krystal Biotech by 15.9% in the third quarter. Public Sector Pension Investment Board now owns 100,431 shares of the company’s stock valued at $17,729,000 after buying an additional 13,743 shares in the last quarter. Atle Fund Management AB increased its holdings in shares of Krystal Biotech by 109.3% in the third quarter. Atle Fund Management AB now owns 42,191 shares of the company’s stock valued at $7,448,000 after buying an additional 22,033 shares in the last quarter. William Blair Investment Management LLC grew its position in Krystal Biotech by 63.9% during the 3rd quarter. William Blair Investment Management LLC now owns 149,302 shares of the company’s stock worth $26,356,000 after purchasing an additional 58,203 shares in the last quarter. Finally, SG Americas Securities LLC grew its position in Krystal Biotech by 469.9% during the 4th quarter. SG Americas Securities LLC now owns 18,909 shares of the company’s stock worth $4,662,000 after purchasing an additional 15,591 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.
Krystal Biotech Company Profile
Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.
The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.
Featured Articles
- Five stocks we like better than Krystal Biotech
- Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader
- 5 Stocks Positioned to Benefit From the AI Inference Boom
- Meta Platforms’ Wild Post-Earnings Swings: Where Analyst Price Targets Stand Now
- 3 Metals and Mining Stocks Riding the Commodity Supercycle
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
